|
|
Effects of Sequential Administration of Moxifloxacin and Levofloxacin on Respiratory Function and Microinflammation in Elderly Patients with Severe AECOPD |
WANG Chao, et al |
Sanya Central Hospital/Hainan Third People's Hospital, Hainan Sanya 572000, China |
|
|
Abstract Objective: To study the effects of sequential administration of moxifloxacin and levofloxacin on respiratory function and microinflammation in elderly patients with severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: 150 elderly patients with severe AECOPD treated in our hospital from March 2019 to March 2022 were selected and divided into group A, B and C by simple random sampling method, with 50 cases in each group. Group A was given moxifloxacin, group B was given levofloxacin, and group C was given moxifloxacin and levofloxacin administered sequentially. The respiratory function indicators [forced expiratory volume in the first second as a percentage of the predicted value (fev1%pred) and forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC)] were compared among the three groups after 1 week of treatment, and the changes of serum microinflammation [intercellular cell adhesion molecule (ICAM)-1, interferon gamma-inducible protein-10 (IP-10)] and immune function [plasma-soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), peripheral blood CD4+/CD8+] were compared and analyzed before and after treatment. The differences in occurrence of adverse drug reactions among the three groups were compared. Results: After 1 week of treatment, fev1%pred, FEV1/FVC and peripheral blood CD4+/CD8+ were increased while serum ICAM-1, IP-10 and plasma sTREM-1 were decreased in the three groups the difference was statistically significant (P<0.05). Compared at the soone time the fev1%pred, FEV1/FVC and peripheral blood CD4+/CD8+ in group A were higher while serum ICAM-1, IP-10 and plasma sTREM-1 were lower than those in group B, and fev1%pred, FEV1/FVC and peripheral blood CD4+/CD8+ were higher while serum ICAM-1, IP-10 and plasma sTREM-1 were lower in group C compared to groups A and B the difference was statistically significant (P<0.05). The incidence rate of phlebitis in group C was lower than that in groups A and B the difference was statistically significant (P<0.05). There were no statistical differences in the incidence rates of other adverse reactions (P>0.05). Conclusion: Sequential administration of moxifloxacin and levofloxacin can alleviate the microinflammatory response in patients with AECOPD, improve the pulmonary function and immune indicators, and effectively prevent the occurrence of phlebitis.
|
|
|
|
|
[1] 秦国双,温昊于,宇传华.中国COPD的患病发病及YLD现状及趋势[J].公共卫生与预防医学,2019,30(2):4-8. [2] 章树佳,吴鸿,袁满,等.两性霉素B脂质体、泊沙康唑序贯治疗侵袭性喉-气管支气管肺曲霉菌病一例[J].中华医学杂志,2019,2(48):3829-3831. [3] 《临床医学研究与实践》编辑部,COPD全球倡议2017年最新指南[J].临床医学研究与实践,2017,2(17):201. [4] 邵远江,黄炳红.AECOPD患者感染呼吸道病毒特征及呼吸道合胞病毒感染与血清IP-10的关系[J].中国病原生物学杂志,2021,16(10):1207-1210,1215. [5] 韩健,付君民,李丽丽,等.宣肺补益汤联合GSH对COPD的疗效及呼吸功能改善效果观察[J].河北医药,2022,44(5):737-739,743. [6] 孔莹.莫西沙星联合常规结核化疗方案治疗耐药性肺结核的临床观察[J].中国冶金工业医学杂志,2022,39(4):441-442. [7] 王勇,王臻颉.喜炎平联合阿奇霉素序贯治疗小儿支原体肺炎的疗效及对微炎症状态和免疫指标的影响[J].中南医学科学杂志,2022,50(5):740-743. [8] 王克俭,李学明.联合检测FeNO、血清sTREM-1、CyPA表达水平在评估COPD患者预后中的价值[J].临床肺科杂志,2019,24(12):2202-2206. |
|
|
|